title: Risks and prevention of severe RS virus infection among children with immunodeficiency and Down's syndrome.
abstract: By the age of two years, almost all infants are infected with the Respiratory syncytial virus (RSV). One of the main causes of hospitalizations for bronchiolitis and pneumonia at this age is RSV infection. In addition to well-known risks for severe RSV disease, such as prematurity, bronchopulmonary dysplasia and congenital heart disease, immunodeficiencies, chromosomal abnormalities such as Down's syndrome or neuromuscular diseases have also been identified as risks. While the medical needs for RSV prevention in these risk groups are high, clinical evidence to support this is limited. Palivizumab was recently approved in Japan for prophylaxis in children with immunodeficiency or Down's syndrome. A clinical guidance protocol for the prevention of RSV infection using Palivizumab in these risk groups is provided here on the basis of a review of the available literature and on expert opinion. Thus, the present article reviews the published literature related to RSV infections in infants and children with immunodeficiencies or Down's syndrome in order to outline the risks, pathology and physiology of severe RSV disease in these patient groups. The purpose of this article is to facilitate understanding of the medical scientific bases for the clinical guidance.
authors.affiliation: Yokohama City University Medical Center, Pediatrics, Japan. Electronic address: mmori@med.yokohama-cu.ac.jp.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Mori
authors.affiliation: Tokyo Medical and Dental University, Department of Pediatrics, Japan.
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Morio
authors.affiliation: National Center for Child Health and Development, Renal, Rheumatism, Collagen Department, Japan.
authors.forename: Shuichi
authors.initials: S
authors.lastname: Ito
authors.affiliation: Jichi Medical University, Department of Pediatrics, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Morimoto
authors.affiliation: Teikyo University Medical Center, Department of Pediatrics, Japan.
authors.forename: Setsuo
authors.initials: S
authors.lastname: Ota
authors.affiliation: Jichi Medical University, Department of Transplant Surgery, Japan.
authors.forename: Koichi
authors.initials: K
authors.lastname: Mizuta
authors.affiliation: Tokyo Kasei University, Pediatrics, Japan.
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Iwata
authors.affiliation: Kyushu University, Graduate School of Medical Sciences, Department of Pediatrics, Japan.
authors.forename: Toshiro
authors.initials: T
authors.lastname: Hara
authors.affiliation: Toho University, Medical Center, Omori Hospital, Department of Pediatrics, Japan.
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Saji
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004314:Down Syndrome / Q000150:complications*; D006801:Humans; D016867:Immunocompromised Host; D007153:Immunologic Deficiency Syndromes / Q000150:complications*; D007223:Infant; D007231:Infant, Newborn; D017053:Infection Control; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control; D012307:Risk Factors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab
keywords: Additional indications; Down's syndrome; Immunodeficiency; Palivizumab; Respiratory syncytial virus